期刊文献+

甲状腺微小乳头状癌右侧喉返神经后方淋巴结转移相关危险因素Meta分析

A Meta-analysis of risk factors related to the lymph nodes posterior to the right recurrent laryngeal nerve in thyroid micropapillary carcinoma
原文传递
导出
摘要 目的:通过Meta分析探讨甲状腺微小乳头状癌(PTMC)右侧喉返神经后方(Ⅵb区)淋巴结转移的危险因素。方法:检索国内外文献数据库中PTMC喉返神经后方淋巴结转移相关的文献,检索截止时间是2020年6月,由两名研究者筛选文献、提取数据后,采用Revman5.3软件进行Meta分析。结果:共纳入5篇文章,共计1884例研究对象,研究结果显示:PTMCⅥb区淋巴结转移率为10.8%(203/1884),转移危险因素包括患者年龄<45岁,男性,右叶肿瘤直径≥0.5 cm,侵出包膜,Ⅵa淋巴结转移。结论:对PTMC有Ⅵb区淋巴结转移高危因素的患者应该行包含Ⅵb区淋巴结在内彻底的淋巴结清扫。 Objective: To evaluate the risk factors for metastasis of the lymph nodes posterior to the right recurrent laryngeal nerve in thyroid micropapillary carcinoma(PTMC) by Meta-analysis. Methods: We searched domestic and foreign databases for relevant studies published up to June, 2020. Two independent reⅥewers performed literature screening and data extraction according to the inclusion and exclusion criteria. Then, Meta-analysis was performed using Revman 5.3 software. Results: A total of 5 articles were included, with a total of 1884 subjects.The results of the study showed that the rate of lymph node metastasis in PTMC Ⅵb area was 10.8%(203/1884). The risk factors for metastasis included patients’ age <45 years old, male, right lobe tumor Diameter ≥0.5 cm, invading the envelope, Ⅵa lymph node metastasis. Conclusion: Ⅵb lymph node dissection is recommended when there exists age<45 years, male sex, right lobe tumor≥0.5 cm, capsular invasion or Ⅵa lymph node metastasis.
作者 王慧芳 于博 赵文君 刘静 WANG Huifang;YU Bo;ZHAO Wenjun;LIU Jing(The First Clinical Medical College,Shanxi Medical University,Taiyuan,030001,China;Department of Thyroid Surgery,the First Hospital of Shanxi Medical University)
出处 《临床耳鼻咽喉头颈外科杂志》 CAS CSCD 北大核心 2021年第3期245-251,共7页 Journal of Clinical Otorhinolaryngology Head And Neck Surgery
基金 山西省重点研发计划项目(No:201903D321147)。
关键词 甲状腺肿瘤 淋巴结转移 颈淋巴结清扫术 喉返神经 META分析 thyroid neoplasms lymphatic metastasis neck dissection recurrent laryngeal nerve Meta-analysis
  • 相关文献

参考文献10

二级参考文献93

  • 1American Thyroid Association (ATA) Guidelines Taskforce on Thy- roid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, et al. Revised American thyroid association manage- ment guidelines for patients with thyroid nodules and differentiat- ed thyroid cancer[J]. Thyroid, 2009, 19(11):1167-1214.
  • 2Haugen BR, Alexander EK, Bible KC, et al. 2015 American thyroid as- sociation management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid as- sociation guidelines task force on thyroid nodules and differentiat- ed thyroid cancer[J]. Thyroid, 2016, 26(1):1-133.
  • 3Tuttle RM, Haddad RI, Ball DW, et al. Thyroid carcinoma, version 2.2014[J]. J Natl Compr Canc Netw, 2014, 12(12):1671-1680.
  • 4Xing MZ. Molecular pathogenesis and mechanisms of thyroid can- cer[J]. Nat Rev Cancer, 2013, 13(3):184-199.
  • 5De Biase D, Gandolfi G, Ragazzi M, et al. TERT promoter mutations in papillary thyroid microcarcinomas[J]. Thyroid, 2015, 25(9):1013- 1019.
  • 6Ito Y, Miyauchi A, Inoue H, et al. An observational trial for papillary thyroid microcarcinoma in Japanese patients[J]. World J Surg, 2010, 34(1):28-35.
  • 7Ito Y, Uruno T, Nakano K, et al. An observation trial without surgical treatment in patients with papillary microcarcinoma of the thyroid [J]. Thyroid, 2003, 13(4):381-387.
  • 8Xing M, Alzahrani AS, Carson KA, et al. Association between BRAF V600E mutation and recurrence of papillary thyroid cancer[J]. J Clin Oncol, 2015, 33(1):42-50.
  • 9Jiang LH, Chen C, Tan Z, et al. Clinical characteristics related to central lymph node metastasis in cN0 papillary thyroid carcinoma: a retro- spective study of 916 patients[J]. Int J Endocrinol, 2014, 2014:385787.
  • 10Ito Y, Fukushima M, Higashiyama T, et al. Tumor size is the strongest predictor of microscopic lymph node metastasis and lymph node recurrence of NO papillary thyroid carcinoma[J]. Endocr J, 2013, 60 (1):113-117.

共引文献554

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部